(Q37810220)

23 August 2017

Therapeutic drug monitoring in cancer chemotherapy (English)

1 reference

23 August 2017

1 reference

Dylan M Bach

1

1 reference

PubMed ID

21083218

23 August 2017

Joely A Straseski

series ordinal

2

1 reference

PubMed ID

21083218

23 August 2017

William Clarke

series ordinal

3

1 reference

23 August 2017

1 May 2010

1 reference

23 August 2017

1 reference

23 August 2017

2

1 reference

23 August 2017

5

1 reference

23 August 2017

863-879

1 reference

Chemotherapy individualization.

23 August 2017

1 reference

Pharmacokinetic variability of anticancer agents

21 January 2018

1 reference

Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy

21 January 2018

1 reference

Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms.

21 January 2018

1 reference

Factors affecting cytochrome P-450 3A activity in cancer patients.

21 January 2018

1 reference

A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer

21 January 2018

1 reference

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

21 January 2018

1 reference

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

21 January 2018

1 reference

Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer.

21 January 2018

1 reference

Determinants of serum antipyrine half-lives in patients with liver disease

21 January 2018

1 reference

Interpatient and intrapatient variability in vinblastine pharmacokinetics

21 January 2018

1 reference

Pharmacokinetic drug interactions of commonly used anticancer drugs.

21 January 2018

1 reference

21 January 2018

1 reference

Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer

21 January 2018

1 reference

Effects of aging on the renal glomerulus

21 January 2018

1 reference

21 January 2018

Aging and pharmacology

1 reference

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment

21 January 2018

1 reference

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

21 January 2018

1 reference

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel

21 January 2018

1 reference

Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

21 January 2018

1 reference

Dosing strategies for anticancer drugs: the good, the bad and body-surface area

21 January 2018

1 reference

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

21 January 2018

1 reference

Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices

21 January 2018

1 reference

Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.

21 January 2018

1 reference

Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

21 January 2018

1 reference

Pharmacokinetically guided administration of chemotherapeutic agents

21 January 2018

1 reference

Therapeutic drug monitoring of cancer chemotherapy.

21 January 2018

1 reference

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

21 January 2018

1 reference

Methotrexate pharmacokinetics and prognosis in osteosarcoma.

21 January 2018

1 reference

Population pharmacokinetics of topotecan: intraindividual variability in total drug.

21 January 2018

1 reference

Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.

21 January 2018

1 reference

Limited sampling models for doxorubicin pharmacokinetics

21 January 2018

1 reference

A limited sampling method for estimation of the carboplatin area under the curve.

21 January 2018

1 reference

Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity

21 January 2018

1 reference

Bayesian estimation and prediction of clearance in high-dose methotrexate infusions.

21 January 2018

1 reference

Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.

21 January 2018

1 reference

Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.

21 January 2018

1 reference

A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.

21 January 2018

1 reference

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer

21 January 2018

1 reference

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

Advances in individual prediction of methotrexate toxicity: a review

21 January 2018

1 reference

Prediction of methotrexate elimination after high dose infusion in children with acute lymphoblastic leukaemia using a population pharmacokinetic approach.

21 January 2018

1 reference

A novel high-performance liquid chromatography/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells

21 January 2018

1 reference

Busulfan in hematopoietic stem cell transplant setting

21 January 2018

1 reference

Therapeutic drug monitoring of busulfan in transplantation

21 January 2018

1 reference

Plasma concentration monitoring of busulfan: does it improve clinical outcome?

21 January 2018

1 reference

Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children : validation of liquid chromatography tandem mass spectrometry method.

21 January 2018

1 reference

In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa)

21 January 2018

1 reference

Population pharmacokinetics of oral busulfan in children

21 January 2018

1 reference

Imatinib mesylate for the treatment of chronic myeloid leukemia

21 January 2018

1 reference

Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation

21 January 2018

1 reference

Monitoring of busulfan area under the curve: estimation by a single measurement

21 January 2018

1 reference

A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan

21 January 2018

1 reference

Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens

21 January 2018

1 reference

The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine

21 January 2018

1 reference

Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics

21 January 2018

1 reference

Determination of busulfan in human plasma using an ELISA format.

21 January 2018

1 reference

Pharmacogenomic studies of the anticancer and immunosuppressive thiopurines mercaptopurine and azathioprine

21 January 2018

1 reference

The clinical pharmacology of 6-mercaptopurine

21 January 2018

1 reference

Therapeutic drug monitoring opportunities in cancer therapy

21 January 2018

1 reference

Targeted inhibition of mammalian target of rapamycin for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

21 January 2018

1 reference

Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.

21 January 2018

1 reference

Limited sampling strategies for the estimation of sirolimus daily exposure in kidney transplant recipients on a calcineurin inhibitor-free regimen.

21 January 2018

1 reference

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma

21 January 2018

1 reference

Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes

21 January 2018

1 reference

Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity

21 January 2018

1 reference

Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer

21 January 2018

1 reference

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

21 January 2018

1 reference

Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders

21 January 2018

1 reference

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

21 January 2018

1 reference

Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans

21 January 2018

1 reference

Cytochrome P450 3A and their regulation

21 January 2018

1 reference

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

21 January 2018

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

Clinical pharmacokinetics of imatinib

21 January 2018

1 reference

Gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

GIST under imatinib therapy

21 January 2018

1 reference

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation

21 January 2018

1 reference

Imatinib plasma levels: correlation with clinical benefit in GIST patients

21 January 2018

1 reference

Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia

21 January 2018

1 reference

Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

21 January 2018

1 reference

Everolimus alters imatinib blood partition in favour of the erythrocyte.

21 January 2018

1 reference

Primary tumor volume of nasopharyngeal carcinoma: prognostic significance for local control

21 January 2018

1 reference

Single-dose clinical pharmacokinetic studies of gefitinib

21 January 2018

1 reference

Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers

21 January 2018

1 reference

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

21 January 2018

1 reference

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

Clinical pharmacokinetics of erlotinib in patients with solid tumors and exposure-safety relationship in patients with non-small cell lung cancer.

21 January 2018

1 reference

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

21 January 2018

1 reference

Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.

21 January 2018

1 reference

Carboplatin dose in combination chemotherapy for testicular cancer

21 January 2018

1 reference

A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.

21 January 2018

1 reference

Population pharmacokinetics of total and unbound etoposide.

21 January 2018

1 reference

Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.

21 January 2018

1 reference

Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.

21 January 2018

1 reference

Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity

21 January 2018

1 reference

21 January 2018

1 reference

Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.4155/BIO.10.48

1 reference

23 August 2017

1 reference

PubMed ID

21083218